From Clinical Strategy to Commercial Success
The Active Pharmaceutical Ingredients (API) products of Oceanix Biotechnology Corporation are all manufactured in our GMP certified factory and in accordance with US GMP protocols. We are committed to provide quality and consistent products with optimum immunogenicity for both your clinical and research needs.
Our aquaculturing facilities and multi-disciplinary laboratories are focused on the continuing discovery and improvement of efficient active pharmaceutical ingredients
Keyhole Limpet Hemocyanin (KLH)
The Company’s principal project, at its R&D and manufacturing facility in Delta, B.C, is its $20 million invested KLH proteins manufacturing project, involving the sustainable, commercial aquaculture of the Giant Keyhole Limpet mollusk and the commercial extraction, purification and production of pharmaceutical grade Hemocyanins (KLH 1, KLH 2, KLH 3), as an adjuvant in anti-cancer drugs and immunotherapy – one of the fastest growing areas of the global biopharmaceuticals industry.
Tetrodotoxin (TTX)
In the Philippines, the company is establishing the commercial production of tetrodotoxin (TTX) from the sustainable supply of local puffer fish and various therapeutic, protein-based, biopharmaceuticals from horseshoe crab blue blood.
Micro & Macro Algaes
The Company is also researching & developing novel anti-cancer therapeutics from various exotic red seaweeds, sea hare excretions and water hyacinth and novel bio-pharmaceuticals from sea cucumbers, along with novel nutraceuticals and functional foods from various species of algae.
